Literature DB >> 18415683

Neuropsychological sequelae of non-central nervous system cancer and cancer therapy.

Jeffrey S Wefel1, Mariana E Witgert, Christina A Meyers.   

Abstract

Cancer patients report numerous adverse symptoms associated with their disease and treatment including cognitive dysfunction, fatigue, and affective distress. Cognitive dysfunction is ubiquitous in patients with primary central nervous system (CNS) cancer and recent evidence has documented similar deficits in patients with non-CNS cancer as well. Both the cancer itself and treatments including chemotherapy, biological response modifiers, and hormonal therapies have been demonstrated to adversely impact cognitive and neurobehavioral function. Neuroimaging and neurophysiological investigations have likewise revealed alterations in brain function that are helping to account for the nature of these cognitive disorders. Similarly, preclinical animal research is assisting to identify the pathophysiological mechanisms that underlie treatment-related neurotoxicities. The coalescence of multidisciplinary clinical and research efforts hold promise for the development of interventions that may offer neuroprotection in addition to currently available symptomatic therapies and cognitive rehabilitation techniques.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18415683     DOI: 10.1007/s11065-008-9058-x

Source DB:  PubMed          Journal:  Neuropsychol Rev        ISSN: 1040-7308            Impact factor:   7.444


  116 in total

1.  Intermediate dose 5-fluorouracil-induced encephalopathy.

Authors:  Yeon-A Kim; Hyun Cheol Chung; Hye Jin Choi; Sun Young Rha; Jin Sil Seong; Hei-Cheul Jeung
Journal:  Jpn J Clin Oncol       Date:  2006-01-25       Impact factor: 3.019

Review 2.  Neurological complications of radiotherapy and chemotherapy.

Authors:  F Keime-Guibert; M Napolitano; J Y Delattre
Journal:  J Neurol       Date:  1998-11       Impact factor: 4.849

3.  Psychologic and neuropsychologic impact of autologous bone marrow transplantation.

Authors:  T A Ahles; D M Tope; C Furstenberg; D Hann; L Mills
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.

Authors:  Arti Hurria; Carol Rosen; Clifford Hudis; Enid Zuckerman; Katherine S Panageas; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea; Mark Moasser; Chau Dang; Catherine Van Poznak; Anju Hurria; Jimmie Holland
Journal:  J Am Geriatr Soc       Date:  2006-06       Impact factor: 5.562

5.  Manic episodes in two patients treated with interferon alpha.

Authors:  D Strite; A D Valentine; C A Meyers
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

6.  The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.

Authors:  V Shilling; V Jenkins; R Morris; G Deutsch; D Bloomfield
Journal:  Breast       Date:  2005-04       Impact factor: 4.380

7.  Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors.

Authors:  M Peper; S Steinvorth; P Schraube; S Fruehauf; R Haas; B N Kimmig; F Lohr; F Wenz; M Wannenmacher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

8.  Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.

Authors:  Kerstin Hermelink; Michael Untch; Michael P Lux; Rolf Kreienberg; Thomas Beck; Ingo Bauerfeind; Karin Münzel
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

Review 9.  Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective.

Authors:  Sanne B Schagen; Martin J Muller; Willem Boogerd; Frits S A M Van Dam
Journal:  Clin Breast Cancer       Date:  2002-12       Impact factor: 3.225

10.  The effects of oestrogens and anti-oestrogens on cognition.

Authors:  V Shilling; V Jenkins; L Fallowfield; A Howell
Journal:  Breast       Date:  2001-12       Impact factor: 4.380

View more
  38 in total

1.  Multi-domain cognitive impairment disclosed before the diagnosis of chronic lymphocytic leukaemia: an autoimmune/paraneoplastic disorder?

Authors:  Silvia Bernardi; Lorenzo De Nardis; Enrica Macci; Marco Fiorelli; Ada Francia
Journal:  Neurol Sci       Date:  2012-06-27       Impact factor: 3.307

2.  Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial.

Authors:  Robert J Ferguson; Brenna C McDonald; Michael A Rocque; Charlotte T Furstenberg; Susan Horrigan; Tim A Ahles; Andrew J Saykin
Journal:  Psychooncology       Date:  2010-12-02       Impact factor: 3.894

3.  Circumstances of suicide among individuals with a history of cancer.

Authors:  Greta M Massetti; Kristin M Holland; Shane P D Jack; Kathleen R Ragan; Natasha Buchanan Lunsford
Journal:  Psychooncology       Date:  2018-04-23       Impact factor: 3.894

Review 4.  Radiation, chemotherapy, and symptom management in cancer-related cognitive dysfunction.

Authors:  Christopher Loiselle; Jason Rockhill
Journal:  Curr Pain Headache Rep       Date:  2009-08

5.  Peripheral tumors alter neuroinflammatory responses to lipopolysaccharide in female rats.

Authors:  Leah M Pyter; Sarah El Mouatassim Bih; Husain Sattar; Brian J Prendergast
Journal:  Brain Res       Date:  2014-01-20       Impact factor: 3.252

6.  Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance.

Authors:  Patricia A Ganz; Lorna Kwan; Steven A Castellon; Amy Oppenheim; Julienne E Bower; Daniel H S Silverman; Steve W Cole; Michael R Irwin; Sonia Ancoli-Israel; Thomas R Belin
Journal:  J Natl Cancer Inst       Date:  2013-04-19       Impact factor: 13.506

7.  Patient-oriented cancer information on the internet: a comparison of wikipedia and a professionally maintained database.

Authors:  Malolan S Rajagopalan; Vineet K Khanna; Yaacov Leiter; Meghan Stott; Timothy N Showalter; Adam P Dicker; Yaacov R Lawrence
Journal:  J Oncol Pract       Date:  2011-08-04       Impact factor: 3.840

8.  Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a population-based comparative study.

Authors:  I Glimelius; S Ekberg; J Linderoth; M Jerkeman; E T Chang; M Neovius; K E Smedby
Journal:  J Cancer Surviv       Date:  2015-02-18       Impact factor: 4.442

9.  Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research.

Authors:  Andrew J Saykin; Michiel B de Ruiter; Brenna C McDonald; Sabine Deprez; Daniel H S Silverman
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

10.  Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?

Authors:  Patricia A Ganz; J E Bower; L Kwan; S A Castellon; D H S Silverman; C Geist; E C Breen; M R Irwin; S W Cole
Journal:  Brain Behav Immun       Date:  2012-08-03       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.